An Overview of EuroQol EQ-5D: Quality-of-Life Assessment
EuroQol EQ-5D explained: How it measures quality of life, supports QALYs and HTA decisions, and what new EuroQol tools mean for clinical trial strategy.
Find out why strategic pharma intelligence is needed to connect insights and to guide confident decision-making across the drug development lifecycle.
Across discovery, clinical development, and commercialisation, pharma leaders are navigating more news, more analysis, and just more “noise” than ever before. But more information hasn’t made decisions easier.
Pharma professionals need strategic pharma intelligence with authority and relevance. They want trusted pharma information that matters and connects, and that will give them the clarity to act with confidence.
Pharma executives are now spending as much time filtering insight as they are using it.
While there is an abundance of information available, much of what passes for good “pharma information” is not built for decision-making. It’s built for visibility.
The problem isn’t the volume of available pharma information. It’s quality, relevance, and reliability.
Industry professionals need information that is:
Good pharma information will help pharma professionals make decisions with the full context and adopt new technologies and practices based on proof and evidence.
Most pharma information online is based on a reactive feed of the latest pharma news. If you rely solely on this sort of reporting, you’re at a competitive disadvantage because you miss opportunities if you react instead of anticipate.
You need a forward-looking lens: To not just know what happened, but why and how. To learn what is actionable and connected to real-world practicalities.
Feedback provided again-and-again across the industry highlights a widening gap between what current pharma information sources provide and what is actually required.
Current information is:
What everyone is asking for isn’t more content but better intelligence.
This is pharma information that is based on:
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
In a sector defined by long drug development timelines and high capital investment, the right information and analysis is crucial.
You certainly don’t want information that can lead to misaligned strategies, delayed drug programmes, and missed opportunities. The cost isn’t just money. It means fewer new drug candidates are discovered, clinical trials stall, and, ultimately, therapies take longer to reach patients and improve lives.
Pharmatica is uniquely positioned to help you navigate the complexity of the modern life sciences industry. Our expert-led analysis and authoritative Pharma Insights will position you to effectively cope with technological and scientific breakthroughs, evolving regulations, and fragile supply chains.
Pharmatica is structured around the reality that no decision exists in isolation. We understand that true insight must connect across the full lifecycle:
Decisions in the pharmaceutical industry are too crucial to be guided by noise. Pharmatica doesn’t add to that noise; we elevate the insights that matter.
Pharmatica combines expert-led analysis with a clear focus on what actually drives outcomes across the drug development lifecycle.
This is where intelligence becomes useful. Where insight becomes actionable.
And where better information leads to better decisions.
Whether accelerating drug discovery or patient recruitment with AI-driven tools, or securing supply chains against global shocks, we’ll help you join the dots that make finding solutions possible.
Pharmatica: Insight. Connection. Impact.
Current pharma information sources are limited because they are siloed, reactive, and often driven by commercial agendas. These limitations prevent leaders from understanding downstream impact, connecting insights across functions, and making fully informed strategic decisions.
Pharma leaders need strategic pharma intelligence that is accurate, connected, and forward-looking. They require insights that prioritise clarity over volume, context over fragmentation, and evidence over hype to support confident, real-world decision-making.
Strategic pharma intelligence is the process of delivering curated, evidence-based insights that support decision-making across the drug development lifecycle. It connects scientific, clinical, regulatory, and commercial insights to provide clarity, reduce risk, and guide long-term strategy.
The risk of relying on reactive pharma news is that organisations make decisions based on past events rather than future insight. This leads to missed opportunities, delayed responses to market shifts, and weaker competitive positioning in a fast-moving pharmaceutical landscape.
Strategic pharma intelligence improves decision-making by providing accurate, contextual, and actionable insights across the full drug development lifecycle. It enables leaders to anticipate risks, evaluate technologies, and make informed choices based on evidence rather than trends.
Pharma information should connect across the full drug development lifecycle because decisions in discovery, clinical development, and manufacturing are interdependent.
A connected view helps leaders understand downstream impact, align strategy across functions, and reduce the risk of misaligned investments.
Why not support Nicole Dale by giving this content a like
Comments (0)